HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 270 filers reported holding HALOZYME THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.26 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $48,542 | +12035.5% | 927 | -91.6% | 0.00% | -100.0% |
Q2 2023 | $400 | -34.9% | 11,087 | -31.1% | 0.00% | -25.0% |
Q1 2023 | $614 | -6.8% | 16,087 | +38.9% | 0.00% | -20.0% |
Q4 2022 | $659 | -99.9% | 11,581 | -62.4% | 0.01% | -44.4% |
Q3 2022 | $1,217,000 | -48.2% | 30,774 | -42.4% | 0.01% | -47.1% |
Q2 2022 | $2,350,000 | +10.3% | 53,398 | 0.0% | 0.02% | +41.7% |
Q1 2022 | $2,130,000 | -83.6% | 53,398 | -83.5% | 0.01% | -82.1% |
Q4 2021 | $13,027,000 | -7.0% | 323,083 | -6.2% | 0.07% | -13.0% |
Q3 2021 | $14,006,000 | +57.6% | 344,302 | +75.9% | 0.08% | +40.0% |
Q2 2021 | $8,887,000 | +8.9% | 195,714 | 0.0% | 0.06% | +1.9% |
Q1 2021 | $8,159,000 | +212.6% | 195,714 | +220.3% | 0.05% | +200.0% |
Q4 2020 | $2,610,000 | +23.2% | 61,100 | -24.2% | 0.02% | +20.0% |
Q3 2020 | $2,118,000 | +144.6% | 80,600 | +149.5% | 0.02% | +114.3% |
Q2 2020 | $866,000 | – | 32,300 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Third Security, LLC | 14,092,771 | $206,177,000 | 28.12% |
BB BIOTECH AG | 8,322,860 | $121,763,000 | 3.90% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 398,633 | $4,579,000 | 2.84% |
DOHENY ASSET MANAGEMENT /CA | 227,193 | $3,324,000 | 2.43% |
SNYDER CAPITAL MANAGEMENT L P | 2,833,759 | $41,458,000 | 2.24% |
First Light Asset Management, LLC | 938,399 | $13,729,000 | 2.19% |
IRIDIAN ASSET MANAGEMENT LLC/CT | 9,027,164 | $132,067,000 | 1.77% |
Taylor Wealth Management Partners | 204,277 | $2,989,000 | 1.72% |
Sterling Global Strategies LLC | 22,000 | $321,860,000 | 1.63% |
Granite Investment Partners, LLC | 988,939 | $14,468,000 | 1.06% |